[3-(1-methylpiperidin-2-yl)phenyl] N,N-dimethylcarbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [3-(1-methylpiperidin-2-yl)phenyl] N,N-dimethylcarbamate
• 化学式: C₁₅H₂₂N₂O₂
• 分子量: 262.352
• InChiKey: DSWNFCNUEMYBKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-(3-甲氧基苯基)-5-氧代戊酸 在 吡啶 、 lithium aluminium tetrahydride 、 氢溴酸 、 sodium hydride 、 formamide 、 三乙胺 作用下， 以 乙醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 [3-(1-methylpiperidin-2-yl)phenyl] N,N-dimethylcarbamate
  参考文献：
  名称：

  Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease

  摘要：

  In order to develop new cholinesterase agents effective against Alzheimer's disease (AD) we synthesized some phenylcarbamates structurally related to Rivastigmine and evaluated their in vitro and in vivo biological activity. Among the compounds which displayed the most significant in vitro activity, 1-[1-(3-dimethylcarbamoyloxyphenyl)ethyl]piperidine (31b), in addition to a simple and cheaper synthesis, showed lower toxicity and very similar therapeutic index in comparison with Rivastigmine. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(01)01324-1

文献信息

• Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease
  作者：C MUSTAZZA、A BORIONI、M GIUDICE、F GATTA、R FERRETTI、A MENEGUZ、M VOLPE、P LORENZINI

  DOI：10.1016/s0223-5234(01)01324-1

  日期：2002.2

  In order to develop new cholinesterase agents effective against Alzheimer's disease (AD) we synthesized some phenylcarbamates structurally related to Rivastigmine and evaluated their in vitro and in vivo biological activity. Among the compounds which displayed the most significant in vitro activity, 1-[1-(3-dimethylcarbamoyloxyphenyl)ethyl]piperidine (31b), in addition to a simple and cheaper synthesis, showed lower toxicity and very similar therapeutic index in comparison with Rivastigmine. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.